Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis

Acta Ophthalmologica - Tập 89 Số 2 - Trang e206-e207 - 2011
Farzin Forooghian1, Emily Y. Chew1, Catherine Meyerle1, Catherine A. Cukras1, Wai T. Wong2
1Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, MD, USA
2Office of the Scientific Director, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Baert, 2003, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease, N Engl J Med, 348, 601, 10.1056/NEJMoa020888

Calabresi, 2007, The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL, Neurology, 69, 1391, 10.1212/01.wnl.0000277457.17420.b5

Forooghian, 2009, Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration, Retina, 29, 723, 10.1097/IAE.0b013e3181a2c1c3

Keane, 2008, Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration, Invest Ophthalmol Vis Sci, 49, 3115, 10.1167/iovs.08-1689

Rosenfeld, 2006, Ranibizumab for neovascular age-related macular degeneration, N Engl J Med, 355, 1419, 10.1056/NEJMoa054481

Schaal, 2008, Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?, Ophthalmology, 115, 2199, 10.1016/j.ophtha.2008.07.007

Thông tin
Thông tin xuất bản

Acta Ophthalmologica

Tập 89 Số 2

e206-e207

Thông tin tác giả